OBJECTIVE: Stillbirth is associated with an increased rate of maternal blood transfusion. However, the association between stillbirth and other conditions within the Centers for Disease Control (CDC)'s severe maternal morbidity (SMM) composite remains unexamined. We aimed to determine whether stillbirth was associated with higher odds of having conditions within the SMM composite compared to livebirth. STUDY DESIGN: This retrospective cohort study used the Florida State Inpatient Database. The first delivery of all Florida residents aged 13 to 55 years old from 2005 to 2014 was included. ICD-9-CM diagnosis codes identified type of birth (stillbirth !23 weeks versus term, singleton liveborn) and presence of SMM during delivery hospitalization. The primary outcome was the CDC's composite of SMM, which includes 21 conditions ranging from acute myocardial infarction or blood transfusion to ventilation. Secondary outcomes included a SMM composite without blood transfusion and individual morbidities within the SMM composite. We compared outcomes after stillbirth !23 weeks to those after term, liveborn singletons using multivariable logistic regression to adjust for mode of delivery and maternal age, race, health insurance type, and income quartile. RESULTS: 9678 women with stillbirth and 1,356,107 with livebirth were included. During delivery, 7.6% of women with stillbirth had SMM including blood transfusion; the odds were more than 6.5 times higher compared to liveborn (adjusted odds ratio (aOR) 6.66 (95% confidence interval (CI) 6.16 e 7.21). Excluding transfusion, 2.5% of women with stillbirth had SMM; the odds were more than 5.5 times higher compared to women with livebirth (aOR 5.55 (95% CI 4.87 e 6.33)). With the exception of severe anesthetic complications, each condition within the composite had significantly higher odds during delivery hospitalization of stillbirth versus term livebirth, particularly for sepsis (0.9% vs 0.06%; aOR 18.95 (95%CI 15.10 e 23.80)), shock (0.5% vs 0.04%; aOR 16.39 (95% CI 11.94 e 22.48)), and acute renal failure (1.1% vs 0.09%; aOR 15.54 (95% CI 12.59 e 19.19)). CONCLUSION: Though blood transfusion is the most common SMM associated with stillbirth, these data suggest nearly all of the conditions within the CDC's SMM composite are significantly more common among women with stillbirth vs. livebirth. Providers and hospitals who deliver women with stillbirth !23 weeks must be prepared to manage all SMM, not only provide blood transfusion.
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814 Racial disparities in maternal critical care -are there racial differences in level of care?
Columbia University Irving Medical Center, New York, NY OBJECTIVE: Obstetric care in the US is complicated by marked racial and ethnic disparities in maternal obstetric outcomes, including severe morbidity and mortality, which are not explained by underlying differences in patient characteristics. Understanding differences in care delivery related to clinical acuity across different racial groups can help elucidate the source of these disparities. This study examined the association of maternal race with utilization of critical care interventions. STUDY DESIGN: This is a secondary analysis of a multicenter observational study of delivery after prior uterine scar. All women with a known delivery date were included. The primary outcome measure, a composite of critical care interventions (CCI) at delivery or postpartum that included mechanical ventilation, central and arterial line placement, and ICU admission were compared by racial/ethnic group enon-Hispanic white, non-Hispanic black, Hispanic, Asian, and Native American. We evaluated differences in utilization of critical care with a multivariable regression model accounting for selected characteristics present at admission for delivery, including maternal age, BMI, co-morbidities, parity, and plurality. We then compared the frequency of CCIs by maternal co-morbidity, specifically heart disease, renal disease, and chronic hypertension, to ascertain the level of care provided to women of different race with specific baseline co-morbidities. RESULTS: 73,096 of 73,257 women in the parent trial met inclusion criteria, of whom 505 (0.7%) received a CCI and 3337 (4.6%) had a significant co-morbidity (1.2% heart disease, 0.8% renal disease, 2.5% chronic hypertension). For the same disease type, the distribution of critical care interventions remained higher for black and Hispanic patients (Figure 1) . However, in the adjusted model, there was no significant association between critical care intervention and race/ethnicity (Table 1) . CONCLUSION: This study suggests that differences in maternal morbidity by race are not accounted for by access to higher intensity of care. Black and Hispanic women with medical co-morbidities received equal or more CCIs than white women. Further investigation into differential disease severity and mechanisms for escalating care may continue to clarify the source of these outcome disparities.
815 Intravenous iron sucrose versus oral ferrous bis-glycinate for treatment of postpartum iron deficiency anemia The study included women who were delivered either vaginally or by cesarean section proved to have a postpartum IDA (hemoglobin < 11 g/dL). Participants were randomized in a 1:1 ratio to the two study groups: Group I: IV iron sucrose group received IV iron sucrose (sacrofer ampules 100 mg/5ml, Amoun Pharmaceutical Company, Egypt) A patient's total body iron deficit were calculated using the Ganzoni formula (total iron dose ¼ [body weight (kg) Â (15-actual Hb)] Â 2.4 + 500 mg) then the total dose was divided on 3 settings. Group II: Oral ferrous bis-glycinate group received oral FBG fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets, DEVART LAB under the license of NOVOTECH, USA) once daily for 42 days. The primary study outcome was the mean rise in Hb level after 6 weeks treatment. RESULTS: The study included 150 women in the final analysis. No difference between both groups regarding the baseline characteristics. The mean increase in HB level after 6 weeks of treatment in IV iron sucrose group was 2.75AE 0.33 g/dL versus 2.45AE0.38 g/dL in FBG group (p¼ 0.001). The percentage of women with Hb level >11 g/dL after 6 weeks of treatment was 89.2% in IV iron sucrose group versus 71.3% in FBG group (p <0.001). The rate of adverse effects was significantly higher in FBG group (p¼ .001) especially nausea and constipation. CONCLUSION: Women with postpartum IDA is better treated with IV iron sucrose which is more efficient in increasing Hb level. Moreover, it has tolerable adverse effects and high compliance than oral FBG.
816 Prediction of Morbidly adherent placenta using ultrasonographic Placenta Accreta Index (PAI) 
OBJECTIVE:
The current study aims to evaluate the accuracy of an ultrasonographic placenta accreta index (PAI) for diagnosing morbidly adherent placenta (MAP). STUDY DESIGN: This study was a prospective cohort study included pregnant women referred to our ultrasound unit in a tertiary university hospital from March 2016 to February 2018 because of suspected MAP on a previous ultrasound examination All women were assessed using the PAI score based on the following: number and size of placental lacunae; presence of bridging vessels; the sagittal smallest myometrial thickness, the uterine-bladder interface thickness and the placental location. Additionally, the number of previous Cesarean deliveries was determined. All ultrasonographic evaluations were performed by an expert level II sonographer.
The presence of MAP was determined by the surgeon at delivery and clinical data were recorded at time of delivery. Pathological diagnoses of placental invasion were available only in patients that underwent hysterectomy. RESULTS: In total, 137 pregnant women were included in the study, of whom 33 (24.1%) were diagnosed with MAP. The mean PAI score in women with focal accreta was significantly higher than the PAI score of placenta previa non-accreta (6.50AE1.81 vs. 3.63AE1.98, p<0.001). Similarly, the mean PAI score in women with total accrete was significantly higher than non-accreta (8.71AE0.28 vs. 3.63AE1.98, p<0.001). Receivereoperating characteristics (ROC) curve for prediction of MAP using PAI score yielded an area under the ROC curve of 0.911. The best cut-off point was 5.25 with 86% sensitivity and 88% specificity. All sonographic criteria of the PAI were significantly associated with MAP (p<0.0001). ROC curves for prediction of MAP using the number of placental lacunae and smallest myometrial thickness yielded an area under the ROC curve of 0.856 and 0.783 respectively. CONCLUSION: PAI is highly predictive of morbidly adherent placenta in patients at risk. This allows an adequate pre-operative planning and accurate timing of delivery in such cases
